Silver Book Fact

Gene transfer process treatment for diabetic retinopathy

A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.

Ramirez M, Wu Z, Moreno-Carranza B, Jeziorski M, et al. Vasoinhibin Gene Transfer by Adenoassociated Virus Type 2 Products Against VEGF-and Diabetes-Induced Retinal Vasopermeability. Invest Opthalmol Vis Sci. 2011; 52(12): 8944-8950. http://www.researchgate.net/publication/51720075_Vasoinhibin_Gene_Transfer_by_Adenoassociated_Virus_Type_2_Protects_against_VEGF-_and_Diabetes-Induced_Retinal_Vasopermeability

Reference

Title
Vasoinhibin Gene Transfer by Adenoassociated Virus Type 2 Products Against VEGF-and Diabetes-Induced Retinal Vasopermeability
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Ramirez M, Wu Z, Moreno-Carranza B, Jeziorski M, et al
Volume & Issue
Volume 52, Issue 12
Pages
8944-8950
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • Multifoca electroretinogram (mFERG) measures show abnormal function of the retina early in–and even prior to–diabetic retinopathy onset and could enhance monitoring of the early stages of disease progression in individuals.  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…  
  • Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).  
  • Detection and treatment of proliferative diabetic eye disease and clincally significant macular edema with laser therapy can reduce severe vision loss progression by 50% to 60%